Neslihan Cuhaci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neslihan Cuhaci has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Bekir Cakir
Department of Endocrinology and Metabolism, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara 06010, Türkiye
21 shared publications - Reyhan Ersoy
Ankara Ataturk Education and Research Hospital
17 shared publications - Cevdet Aydin
Yildirim Beyazit University, Ataturk Education and Research Hospital, Endocrinology and Metabolism Department, Ankara, Turkey
10 shared publications - Didem Ozdemir
Department of Endocrinology and Metabolism, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara 06800, Turkey
6 shared publications Husniye Baser
Department of Endocrinology and Metabolism, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey
6 shared publicationsBurcak Polat
Ataturk Education and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey
5 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2772
Diagnostic Utility of ACTH, Cortisol, DHEAS, and Their Derived Ratios in Cushing’s Syndrome Subtypes
Background/Objectives: Differentiating Cushing’s disease (CD) from adrenocorticotropic hormone (ACTH)-independent Cushing’s syndrome (AICS) remains challenging in patients with equivocal ACTH levels. While dynamic testing is frequently required, baseline hormonal measurements may offer a simpler diagnostic approach. We aim to evaluate the diagnostic value of baseline plasma ACTH, cortisol, and dehydroepiandrosterone sulfate (DHEAS) levels and their derived ratios for differentiation between ACTH-dependent and ACTH-independent Cushing’s syndrome, and to propose a diagnostic algorithm based on these parameters. Methods: This retrospective single-centre study included adult patients with endogenous Cushing’s syndrome aged 18–75 years who were followed at our institution. Patients with ectopic/paraneoplastic Cushing’s syndrome were excluded. The AICS group comprised overt adrenal CS and mild autonomous cortisol secretion cases. Morning baseline plasma ACTH (pg/mL), serum cortisol (µg/dL), and serum DHEAS (µg/dL) levels were measured and ratios calculated: cortisol-to-ACTH ratio (CAR), DHEAS-to-cortisol ratio (DCR), and CAR-to-DHEAS ratio (CAR/D). ROC analysis assessed diagnostic performance with age and sex adjustments. Results: A total of 100 patients were included, comprising 43 patients with CD and 57 with AICS. Plasma ACTH demonstrated high diagnostic accuracy for identifying CD with a cut-off of ≥14.65 pg/mL (sensitivity 100%, specificity 98.25%, AUC 0.998). Serum DHEAS showed strong discriminative power with a cut-off of ≥67.15 µg/dL (sensitivity 88.37%, specificity 91.23%, AUC 0.925), achieving high discriminative power after age–sex adjustment at ≥85.59 µg/dL (sensitivity 100%, specificity 100%, AUC 0.999). CAR showed good performance in identifying CD with a cut-off of ≤0.75 µg/dL per pg/mL (sensitivity 93.02%, specificity 98.25%, AUC 0.980). CAR/D demonstrated high diagnostic power with a cut-off of ≤1.54 (sensitivity 95.35%, specificity 98.25%, AUC 0.974), improving after age–sex adjustment to ≤2.36 (sensitivity 97.87%, specificity 96.23%, AUC 0.992). Conclusions: Baseline plasma ACTH, serum cortisol, and serum DHEAS measurements, along with derived ratios—especially CAR and CAR/D—provide highly accurate differentiation between ACTH-dependent and ACTH-independent Cushing’s syndrome. These widely available measurements may reduce dependence on dynamic testing and improve diagnostic accuracy in patients with equivocal findings.
- 7 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2772
Open AccessDiagnostic Utility of ACTH, Cortisol, DHEAS, and Their Derived Ratios in Cushing’s Syndrome Subtypes
Background/Objectives: Differentiating Cushing’s disease (CD) from adrenocorticotropic hormone (ACTH)-independent Cushing’s syndrome (AICS) remains challenging in patients with equivocal ACTH levels. While dynamic testing is frequently required, baseline hormonal measurements may offer a simpler diagnostic approach. We aim to evaluate the diagnostic value of baseline plasma ACTH, cortisol, and dehydroepiandrosterone sulfate (DHEAS) levels and their derived ratios for differentiation between ACTH-dependent and ACTH-independent Cushing’s syndrome, and to propose a diagnostic algorithm based on these parameters. Methods: This retrospective single-centre study included adult patients with endogenous Cushing’s syndrome aged 18–75 years who were followed at our institution. Patients with ectopic/paraneoplastic Cushing’s syndrome were excluded. The AICS group comprised overt adrenal CS and mild autonomous cortisol secretion cases. Morning baseline plasma ACTH (pg/mL), serum cortisol (µg/dL), and serum DHEAS (µg/dL) levels were measured and ratios calculated: cortisol-to-ACTH ratio (CAR), DHEAS-to-cortisol ratio (DCR), and CAR-to-DHEAS ratio (CAR/D). ROC analysis assessed diagnostic performance with age and sex adjustments. Results: A total of 100 patients were included, comprising 43 patients with CD and 57 with AICS. Plasma ACTH demonstrated high diagnostic accuracy for identifying CD with a cut-off of ≥14.65 pg/mL (sensitivity 100%, specificity 98.25%, AUC 0.998). Serum DHEAS showed strong discriminative power with a cut-off of ≥67.15 µg/dL (sensitivity 88.37%, specificity 91.23%, AUC 0.925), achieving high discriminative power after age–sex adjustment at ≥85.59 µg/dL (sensitivity 100%, specificity 100%, AUC 0.999). CAR showed good performance in identifying CD with a cut-off of ≤0.75 µg/dL per pg/mL (sensitivity 93.02%, specificity 98.25%, AUC 0.980). CAR/D demonstrated high diagnostic power with a cut-off of ≤1.54 (sensitivity 95.35%, specificity 98.25%, AUC 0.974), improving after age–sex adjustment to ≤2.36 (sensitivity 97.87%, specificity 96.23%, AUC 0.992). Conclusions: Baseline plasma ACTH, serum cortisol, and serum DHEAS measurements, along with derived ratios—especially CAR and CAR/D—provide highly accurate differentiation between ACTH-dependent and ACTH-independent Cushing’s syndrome. These widely available measurements may reduce dependence on dynamic testing and improve diagnostic accuracy in patients with equivocal findings.
- Open Access
Seasonal Changes in Thyrotropin and Thyroid Hormones in Women of Reproductive Age
Background: Thyroid hormones are essential for the proper functioning of the female reproductive system. Seasonal changes in thyroid hormones in women of reproductive age are not fully understood. we aimed to investigate seasonal changes in thyrotrophin and thyroid hormones in women of reproductive age. Methods: Approximately 75,000 TSH and thyroid hormone levels measured in 32,935 women between 2019 and 2023 were evaluated on a monthly and seasonal basis. The analysis of means (ANOM) method was utilized to compare the mean transformed rank of each group or the overall mean transformed rank for TSH, FT3, and FT4 values across months and seasons. Results: The differences from the maximum to minimum median values were 13.3% for TSH, 5.2% for free T3, and 5.9% for free T4. TSH levels were significantly lower in summer and autumn and higher in winter and spring than the overall transformed mean. The rate of individuals with TSH levels below 2.5 mIU/L was higher in summer and autumn than in spring and winter. Conclusions: TSH varies seasonally in women of reproductive age. It is appropriate to consider the season as well as other parameters that affect thyroid functions while evaluating thyroid hormones.
Open AccessSeasonal Changes in Thyrotropin and Thyroid Hormones in Women of Reproductive Age
Background: Thyroid hormones are essential for the proper functioning of the female reproductive system. Seasonal changes in thyroid hormones in women of reproductive age are not fully understood. we aimed to investigate seasonal changes in thyrotrophin and thyroid hormones in women of reproductive age. Methods: Approximately 75,000 TSH and thyroid hormone levels measured in 32,935 women between 2019 and 2023 were evaluated on a monthly and seasonal basis. The analysis of means (ANOM) method was utilized to compare the mean transformed rank of each group or the overall mean transformed rank for TSH, FT3, and FT4 values across months and seasons. Results: The differences from the maximum to minimum median values were 13.3% for TSH, 5.2% for free T3, and 5.9% for free T4. TSH levels were significantly lower in summer and autumn and higher in winter and spring than the overall transformed mean. The rate of individuals with TSH levels below 2.5 mIU/L was higher in summer and autumn than in spring and winter. Conclusions: TSH varies seasonally in women of reproductive age. It is appropriate to consider the season as well as other parameters that affect thyroid functions while evaluating thyroid hormones.
- Open Access
- 1 December 2019
- Published by Bioscientifica in Endocrine Connections
- Vol. 8 (12) , 1579-1590
Ultrasound elastography score and strain index in different parathyroid lesions
BACKGROUND: Despite significant improvement in imaging quality and advanced scientific knowledge, it may still sometimes be difficult to distinguish different parathyroid lesions. The aims of this prospective study were to evaluate parathyroid lesions with ultrasound elastography and to determine whether strain index can help to differentiate parathyroid lesions. METHODS: Patients with biochemically confirmed hyperparathyroidism and localised parathyroid lesions in ultrasonography were included. All patients underwent B-mode US and USE examination. Ultrasound elastography scores and strain index of lesions were determined. Strain index was defined as the ratio of strain of the thyroid paranchyma to the strain of the parathyroid lesion. RESULTS: Data of 245 lesions of 230 patients were analysed. Histopathologically, there were 202 (82.45%) parathyroid adenomas, 26 (10.61%) atypical parathyroid adenomas, and 17 (6.94%) cases of parathyroid hyperplasia. Median serum Ca was significantly higher in atypical parathyroid adenoma patients than parathyroid hyperplasia patients (P = 0.019) and median PTH was significantly higher in APA compared to PA patients (P<0.001). In 221 (90.2%) of the parathyroid lesions, USE score was 1 or 2. The median SI of atypical parathyroid adenomas was significantly higher than parathyroid adenomas and hyperplasia lesions [1.5 (0.56-4.86), 1.01 (0.21-8.43) and 0.91 (0.26-2.02), respectively, P = 0.003]. CONCLUSION: Our study revealed that SI of parathyroid lesions as well as serum calcium, parathyroid hormone levels, and B-mode US features may help to predict the atypical parathyroid adenoma. Ulrasound elastography can be used to differentiate among parathyroid lesions and guide a surgical approach.
- 1 December 2019
- Published by Bioscientifica in Endocrine Connections
- Vol. 8 (12) , 1579-1590
Open AccessUltrasound elastography score and strain index in different parathyroid lesions
BACKGROUND: Despite significant improvement in imaging quality and advanced scientific knowledge, it may still sometimes be difficult to distinguish different parathyroid lesions. The aims of this prospective study were to evaluate parathyroid lesions with ultrasound elastography and to determine whether strain index can help to differentiate parathyroid lesions. METHODS: Patients with biochemically confirmed hyperparathyroidism and localised parathyroid lesions in ultrasonography were included. All patients underwent B-mode US and USE examination. Ultrasound elastography scores and strain index of lesions were determined. Strain index was defined as the ratio of strain of the thyroid paranchyma to the strain of the parathyroid lesion. RESULTS: Data of 245 lesions of 230 patients were analysed. Histopathologically, there were 202 (82.45%) parathyroid adenomas, 26 (10.61%) atypical parathyroid adenomas, and 17 (6.94%) cases of parathyroid hyperplasia. Median serum Ca was significantly higher in atypical parathyroid adenoma patients than parathyroid hyperplasia patients (P = 0.019) and median PTH was significantly higher in APA compared to PA patients (P<0.001). In 221 (90.2%) of the parathyroid lesions, USE score was 1 or 2. The median SI of atypical parathyroid adenomas was significantly higher than parathyroid adenomas and hyperplasia lesions [1.5 (0.56-4.86), 1.01 (0.21-8.43) and 0.91 (0.26-2.02), respectively, P = 0.003]. CONCLUSION: Our study revealed that SI of parathyroid lesions as well as serum calcium, parathyroid hormone levels, and B-mode US features may help to predict the atypical parathyroid adenoma. Ulrasound elastography can be used to differentiate among parathyroid lesions and guide a surgical approach.
- 31 December 2018
- Published by Elsevier in Surgical Oncology
- Vol. 28, 145-149
Preoperative predictors and prognosis of bilateral multifocal papillary thyroid carcinomas
- 31 December 2018
- Published by Elsevier in Surgical Oncology
- Vol. 28, 145-149
Preoperative predictors and prognosis of bilateral multifocal papillary thyroid carcinomas
- Open Access
- 1 September 2017
- Published by Elsevier in Asian Journal of Surgery
- Vol. 40 (5) , 338-344
Concomitant thyroid lesions in patients with primary hyperparathyroidism
- 1 September 2017
- Published by Elsevier in Asian Journal of Surgery
- Vol. 40 (5) , 338-344
Open AccessConcomitant thyroid lesions in patients with primary hyperparathyroidism
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Case report: endoscopic ultrasonography can be used as an adjunctive procedure in atypically localized and conventional ultrasound negative parathyroid adenoma
Introduction: Ectopic and atypically localized parathyroid adenomas such as in the anterior mediastinum, paraesophageal or retrotracheal position, although rare, can be seen in clinical practice. Ultrasound (US) which is a frequently used and one of the best conventional imaging modality sometimes fails to identify the lesion especially in atypically localized adenomas. Endoscopic US (EUS) is a new technique that can be used for localization of parathyroid lesions. We reported a case with paraeosophageal parathyroid adenoma which was localized accurately with EUS. Case: A 55-year-old woman with papillary thyroid microcarcinoma (PTMC) (0.8 cm in size) was operated 5 years ago. After the thyroid surgery her Ca levels (10.5–11 mg/dl) were found as elevated. She had been evaluated for hypercalcemia and PTH level was also found elevated. In her neck ultrasound (US) and parathyroid scintigraphy no pathology was found. Since she had no operation indication for asymptomatic hyperparathyroidism she had been followed for 5 years. Bone mineral densitometry revealed osteoporosis in lumbal vertebraes. Neck US found no pathology. Recent parathyroid scintigraphy revealed parathyroid adenoma in the posterior of the trachea in the inferior thyroid region. Neck and upper mediastinal computerised tomography showed heterogenous solid nodular lesion in the superior right paraeosophageal region 11 mm in size. In order to determine the exact localization of the parathyroid adenoma EUS was performed and detected a hypoechoic lesion close to esophagus on the right parathyroid localization. The patient underwent parathyroidectomy with minimally invasive procedure, parathyroid adenoma was detected and excised. Conclusion: Preoperative localization of parathyroid pathology is important in appropriate cases of minimal invasive surgery. EUS can be accepted as a tool for detection of parathyroid adenoma. When the other imaging methods are negative or conflicting, EUS can be considered in these patients.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Case report: endoscopic ultrasonography can be used as an adjunctive procedure in atypically localized and conventional ultrasound negative parathyroid adenoma
Introduction: Ectopic and atypically localized parathyroid adenomas such as in the anterior mediastinum, paraesophageal or retrotracheal position, although rare, can be seen in clinical practice. Ultrasound (US) which is a frequently used and one of the best conventional imaging modality sometimes fails to identify the lesion especially in atypically localized adenomas. Endoscopic US (EUS) is a new technique that can be used for localization of parathyroid lesions. We reported a case with paraeosophageal parathyroid adenoma which was localized accurately with EUS. Case: A 55-year-old woman with papillary thyroid microcarcinoma (PTMC) (0.8 cm in size) was operated 5 years ago. After the thyroid surgery her Ca levels (10.5–11 mg/dl) were found as elevated. She had been evaluated for hypercalcemia and PTH level was also found elevated. In her neck ultrasound (US) and parathyroid scintigraphy no pathology was found. Since she had no operation indication for asymptomatic hyperparathyroidism she had been followed for 5 years. Bone mineral densitometry revealed osteoporosis in lumbal vertebraes. Neck US found no pathology. Recent parathyroid scintigraphy revealed parathyroid adenoma in the posterior of the trachea in the inferior thyroid region. Neck and upper mediastinal computerised tomography showed heterogenous solid nodular lesion in the superior right paraeosophageal region 11 mm in size. In order to determine the exact localization of the parathyroid adenoma EUS was performed and detected a hypoechoic lesion close to esophagus on the right parathyroid localization. The patient underwent parathyroidectomy with minimally invasive procedure, parathyroid adenoma was detected and excised. Conclusion: Preoperative localization of parathyroid pathology is important in appropriate cases of minimal invasive surgery. EUS can be accepted as a tool for detection of parathyroid adenoma. When the other imaging methods are negative or conflicting, EUS can be considered in these patients.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Ultrasonographical, clinical and histopathological features of 1264 nodules with papillary thyroid carcinoma and microcarcinoma based on tumor size
Introduction: In recent years, due to the improvements in ultrasonography (US), it has become possible to gain more information about the papillary throid carcinoma (PTC) and papillary tyroid microcarcinoma (PTMC). However, whether PTC and PTMC exhibit the same ultrasonographic features and behave same features is controversial. We aimed to evaluate the patients diagnosed with PTC and PTMC in terms of clinical, ultrasonographical (US) and histopathological features and their relationships with tumor size. Methods: We retrospectively evaluated 881 patients who underwent thyroid surgery between 2007 and 2014 in our clinic and diagnosed with PTC histopathologically were enrolled the study. Demographic characteristics, US findings and histopathological features were evaluated. Results: In total, 1264 nodules were identified in the 881 patients. The incidentality rates were higher in the PTMC group and also in the ≤5 mm group. In total multifocality rate was 32.9%, and it was significantly higher in PTMC group than the PTC group. PTC and >5 mm PTMC groups compared to PTMC and ≤5 mm groups respectively, were more aggresive histopathological features Conclusion: Since the incidentality rates were found significantly more common in our patients with PTMC and those with ≤5 mm, ultrasonographic features of the nodules should be evaluated carefully and for cases which are suspicious with US, US-guided fine needle aspiration biopsy (FNAB) should be considered in order to make the correct treatment strategy. Also our study revealed that PTC and >5 mm PTMC groups compared to PTMC and ≤5 mm groups respectively, have more aggresive histopathological features.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Ultrasonographical, clinical and histopathological features of 1264 nodules with papillary thyroid carcinoma and microcarcinoma based on tumor size
Introduction: In recent years, due to the improvements in ultrasonography (US), it has become possible to gain more information about the papillary throid carcinoma (PTC) and papillary tyroid microcarcinoma (PTMC). However, whether PTC and PTMC exhibit the same ultrasonographic features and behave same features is controversial. We aimed to evaluate the patients diagnosed with PTC and PTMC in terms of clinical, ultrasonographical (US) and histopathological features and their relationships with tumor size. Methods: We retrospectively evaluated 881 patients who underwent thyroid surgery between 2007 and 2014 in our clinic and diagnosed with PTC histopathologically were enrolled the study. Demographic characteristics, US findings and histopathological features were evaluated. Results: In total, 1264 nodules were identified in the 881 patients. The incidentality rates were higher in the PTMC group and also in the ≤5 mm group. In total multifocality rate was 32.9%, and it was significantly higher in PTMC group than the PTC group. PTC and >5 mm PTMC groups compared to PTMC and ≤5 mm groups respectively, were more aggresive histopathological features Conclusion: Since the incidentality rates were found significantly more common in our patients with PTMC and those with ≤5 mm, ultrasonographic features of the nodules should be evaluated carefully and for cases which are suspicious with US, US-guided fine needle aspiration biopsy (FNAB) should be considered in order to make the correct treatment strategy. Also our study revealed that PTC and >5 mm PTMC groups compared to PTMC and ≤5 mm groups respectively, have more aggresive histopathological features.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Malignancy is associated with microcalcification and AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS/FLUS) in cytology
Introduction: The predictors of malignancy are important for decision of appropriate management in nodules with atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS). Our aim was to determine the ultrasonographical, clinical and biochemical predictors of malignancy in these patients. Methods: A total of 427 patients with Bethesda Category III (AUS/FLUS) thyroid nodules were included in this retrospective study. We divided the nodules into two subgroups according to the histopathology as benign and malignant, and compared the preoperative ultrasonographical, clinical and biochemical findings. Results: In overall, 427 patients with 449 AUS/FLUS nodules that went on surgery, the rate of malignancy was 23.4% (105/449). When evaluated seperately, the rate of malignancy was 25.8% in nodules with AUS (82/318) and 17.6% in nodules with FLUS (23/131) (P=0.061). The vast majority of malignant specimens in histopathology consisted of papillary thyroid carcinoma (PTC) (n=91, 86.7%). Preoperative ultrasonographic features of 105 malignant nodules in histopathology were compared with the 344 benign nodules. AP/T ratio was significantly higher in malignant group compared to benign group (P=0.013). In multiple logistic analyses, we found that AP/T ratio, and microcalcification were independently correlated with malignancy (P0.05). Conclusion: In Bethesda Category III nodules with higher AP/T ratio and microcalcification, surgery might be considered as the first theurapeutic option instead of repeat FNAB or observation.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Malignancy is associated with microcalcification and AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS/FLUS) in cytology
Introduction: The predictors of malignancy are important for decision of appropriate management in nodules with atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS). Our aim was to determine the ultrasonographical, clinical and biochemical predictors of malignancy in these patients. Methods: A total of 427 patients with Bethesda Category III (AUS/FLUS) thyroid nodules were included in this retrospective study. We divided the nodules into two subgroups according to the histopathology as benign and malignant, and compared the preoperative ultrasonographical, clinical and biochemical findings. Results: In overall, 427 patients with 449 AUS/FLUS nodules that went on surgery, the rate of malignancy was 23.4% (105/449). When evaluated seperately, the rate of malignancy was 25.8% in nodules with AUS (82/318) and 17.6% in nodules with FLUS (23/131) (P=0.061). The vast majority of malignant specimens in histopathology consisted of papillary thyroid carcinoma (PTC) (n=91, 86.7%). Preoperative ultrasonographic features of 105 malignant nodules in histopathology were compared with the 344 benign nodules. AP/T ratio was significantly higher in malignant group compared to benign group (P=0.013). In multiple logistic analyses, we found that AP/T ratio, and microcalcification were independently correlated with malignancy (P0.05). Conclusion: In Bethesda Category III nodules with higher AP/T ratio and microcalcification, surgery might be considered as the first theurapeutic option instead of repeat FNAB or observation.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Chronic lymphocytic leukemia in an acromegalic patient
Introduction: Acromegaly patients are known to have an increased risk of malignancies. This may be as a result of the effect of insulin-like growth factor I (IGF-I) on cellular proliferation and apoptosis inhibition. Although there are various reports related with hematological malignancies in children who treated with growth hormone (GH), few data are available about hematological malignancies in acromegaly patients. Here, we report a patient with acromegaly who has been developed chronic lypmhocytic leukemia (CLL) in the follow-up period. Case: A 30-year-old woman who was at 25th weeks gestation were consulted for gestational diabetes mellitus 9 years ago. Physical examination, random GH, IGF-I levels and glucose suppression test results were consistent with acromegaly. She reached full term without treatment and had a caesarian section and delivered a 4200-gr-baby boy with Apgar score of 9. After 1 year delivery transsphenoidal surgery was performed and 3 months after the operation long-acting somatostatin analog treatment was begun. Since she had residual adenoma and biochemical remission was not achieved with medical treatment, she had underwent second operation after 1 year later the first surgery. Since the remission was not achieved despite the medical treatment, after 1 year later the second operation gamma-knife therapy has been performed. After 5 years later the radiotherapy, GH and IGF-I levels were decreased gradually, somatostatin therapy was lowered and finally discontinued. However, the patient had progressive leukocytosis with 90% lymphocytes. Flowcytometric analysis of the peripheral blood was consisted with CD5+, CD19+, CD20+, CD22+, CD79b+, CD43+, CD200+ lymphocytes with surface anti-kappa monoclonality. Fluorescent in situ hybridization analysis of bone marrow aspiration revealed 20% deletion 17p13.1(TP53). Her findings were consistent with CLL-stage II. Conclusion: Occurrence of CLL in the course of acromegaly may have been caused by excessive endogenous GH or may be a coincidental situation.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Chronic lymphocytic leukemia in an acromegalic patient
Introduction: Acromegaly patients are known to have an increased risk of malignancies. This may be as a result of the effect of insulin-like growth factor I (IGF-I) on cellular proliferation and apoptosis inhibition. Although there are various reports related with hematological malignancies in children who treated with growth hormone (GH), few data are available about hematological malignancies in acromegaly patients. Here, we report a patient with acromegaly who has been developed chronic lypmhocytic leukemia (CLL) in the follow-up period. Case: A 30-year-old woman who was at 25th weeks gestation were consulted for gestational diabetes mellitus 9 years ago. Physical examination, random GH, IGF-I levels and glucose suppression test results were consistent with acromegaly. She reached full term without treatment and had a caesarian section and delivered a 4200-gr-baby boy with Apgar score of 9. After 1 year delivery transsphenoidal surgery was performed and 3 months after the operation long-acting somatostatin analog treatment was begun. Since she had residual adenoma and biochemical remission was not achieved with medical treatment, she had underwent second operation after 1 year later the first surgery. Since the remission was not achieved despite the medical treatment, after 1 year later the second operation gamma-knife therapy has been performed. After 5 years later the radiotherapy, GH and IGF-I levels were decreased gradually, somatostatin therapy was lowered and finally discontinued. However, the patient had progressive leukocytosis with 90% lymphocytes. Flowcytometric analysis of the peripheral blood was consisted with CD5+, CD19+, CD20+, CD22+, CD79b+, CD43+, CD200+ lymphocytes with surface anti-kappa monoclonality. Fluorescent in situ hybridization analysis of bone marrow aspiration revealed 20% deletion 17p13.1(TP53). Her findings were consistent with CLL-stage II. Conclusion: Occurrence of CLL in the course of acromegaly may have been caused by excessive endogenous GH or may be a coincidental situation.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
A patient with radiological dilemma: hemorrhagic pituitary adenoma or rathke's cleft cyst?
Introduction: Rathke’s cleft cyst is one of the pituitary non-adenomatous tumors that found in about 20% of pituitary glands at autopsy. Symptomatic Rathke’s cleft cysts are rarely, but these cysts can cause serious medical problems associated with compression of the pituitary gland, pituitary stalk, optic nerve or hypothalamus. Here, we report a rare case of 73 years old man with sudden onset headache due to Rathke’s cleft cyst present with symptoms and radiological features like apoplexy of pituitary adenoma. Case: A 73-year-old man admitted to our hospital with weight loss and sudden onset headache. His body mass index were 31.8 kg/m2, blood pressure: 120/84 mmHg and 68 per min with a regular rhythm. Neurologic examination was normal. Laboratory findings were as follows: CBC was normal, Serum sodium: 138 mmol/l, potassium: 4.8 mmol/l, urea nitrogen: 35 mg/dl, creatinine: 1.1 mg/dl, fasting plasma glucose: 102 mg/dl, hemoglobin A1c: 7.3%. Anterior pituitary function tests were as follows: morning serum cortisol 0.99 μg/dl, Adrenocorticotrophic hormone (ACTH) 14.2 pg/ml, free T3 1.82 μg/dl, free T4 1.32 μg/dl, thyroid stimulating hormone (TSH) 2.36 mIU/ml, luteinizing hormone (LH) 1.18 mIU/ml, follicle stimulating hormone (FSH) 2.47 mIU/ml, serum testosterone <0.0025 ng/dl and serum prolactin of 12 ng/ml. His laboratory tests revealed panhypopituitarism. Brain magnetic resonance imaging (MRI) showed a 20×15 cm sized sellar cystic lesion, which consisted of a Rathke’s cleft cyst. On the basis of these results, supplementation with thyroid hormone and glucocorticoid was started. After 1 month of supplementation treatment control MRI showed a 8.7×4.3 cm Rathke’s cleft cyst which was regressed compared to initial imaging. Conclusion: The neurologic symptoms of endocrinopathies can be associated with Rathke’s cleft cyst and hemorrhagic pituitary adenoma. The radiological evaluation can be spurious in these patients. Longer follow-up must be needed in order to confirm the exact diagnosis.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
A patient with radiological dilemma: hemorrhagic pituitary adenoma or rathke's cleft cyst?
Introduction: Rathke’s cleft cyst is one of the pituitary non-adenomatous tumors that found in about 20% of pituitary glands at autopsy. Symptomatic Rathke’s cleft cysts are rarely, but these cysts can cause serious medical problems associated with compression of the pituitary gland, pituitary stalk, optic nerve or hypothalamus. Here, we report a rare case of 73 years old man with sudden onset headache due to Rathke’s cleft cyst present with symptoms and radiological features like apoplexy of pituitary adenoma. Case: A 73-year-old man admitted to our hospital with weight loss and sudden onset headache. His body mass index were 31.8 kg/m2, blood pressure: 120/84 mmHg and 68 per min with a regular rhythm. Neurologic examination was normal. Laboratory findings were as follows: CBC was normal, Serum sodium: 138 mmol/l, potassium: 4.8 mmol/l, urea nitrogen: 35 mg/dl, creatinine: 1.1 mg/dl, fasting plasma glucose: 102 mg/dl, hemoglobin A1c: 7.3%. Anterior pituitary function tests were as follows: morning serum cortisol 0.99 μg/dl, Adrenocorticotrophic hormone (ACTH) 14.2 pg/ml, free T3 1.82 μg/dl, free T4 1.32 μg/dl, thyroid stimulating hormone (TSH) 2.36 mIU/ml, luteinizing hormone (LH) 1.18 mIU/ml, follicle stimulating hormone (FSH) 2.47 mIU/ml, serum testosterone <0.0025 ng/dl and serum prolactin of 12 ng/ml. His laboratory tests revealed panhypopituitarism. Brain magnetic resonance imaging (MRI) showed a 20×15 cm sized sellar cystic lesion, which consisted of a Rathke’s cleft cyst. On the basis of these results, supplementation with thyroid hormone and glucocorticoid was started. After 1 month of supplementation treatment control MRI showed a 8.7×4.3 cm Rathke’s cleft cyst which was regressed compared to initial imaging. Conclusion: The neurologic symptoms of endocrinopathies can be associated with Rathke’s cleft cyst and hemorrhagic pituitary adenoma. The radiological evaluation can be spurious in these patients. Longer follow-up must be needed in order to confirm the exact diagnosis.